HRP20110054T1 - Derivat triazolona - Google Patents

Derivat triazolona Download PDF

Info

Publication number
HRP20110054T1
HRP20110054T1 HR20110054T HRP20110054T HRP20110054T1 HR P20110054 T1 HRP20110054 T1 HR P20110054T1 HR 20110054 T HR20110054 T HR 20110054T HR P20110054 T HRP20110054 T HR P20110054T HR P20110054 T1 HRP20110054 T1 HR P20110054T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
dihydro
oxo
methyl
acceptable salt
Prior art date
Application number
HR20110054T
Other languages
English (en)
Croatian (hr)
Inventor
Clark Richard
Matsuura Fumiyoshi
Kira Kazunobu
Hirota Shinsuke
Azuma Hiroshi
Nagakura Tadashi
Horizoe Tatsuo
Tabata Kimiyo
Kusano Kazutomi
Omae Takao
Inoue Atsushi
Original Assignee
Eisai R&D Management Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co. filed Critical Eisai R&D Management Co.
Publication of HRP20110054T1 publication Critical patent/HRP20110054T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20110054T 2006-03-24 2007-03-22 Derivat triazolona HRP20110054T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2006083486 2006-03-24
US78668706P 2006-03-29 2006-03-29
JP2006162594 2006-06-12
US80487806P 2006-06-15 2006-06-15
JP2006218819 2006-08-10
US83841806P 2006-08-18 2006-08-18
PCT/JP2007/055813 WO2007111212A1 (fr) 2006-03-24 2007-03-22 Dérivé de triazolone

Publications (1)

Publication Number Publication Date
HRP20110054T1 true HRP20110054T1 (hr) 2011-02-28

Family

ID=38950011

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110054T HRP20110054T1 (hr) 2006-03-24 2007-03-22 Derivat triazolona

Country Status (25)

Country Link
US (3) US7816522B2 (fr)
EP (2) EP2000465B1 (fr)
JP (1) JP5016592B2 (fr)
KR (1) KR101362024B1 (fr)
AT (2) ATE491694T1 (fr)
AU (1) AU2007230346B2 (fr)
BR (1) BRPI0709101A2 (fr)
CA (1) CA2647423C (fr)
CY (1) CY1111271T1 (fr)
DE (1) DE602007011231D1 (fr)
DK (1) DK2000465T3 (fr)
HR (1) HRP20110054T1 (fr)
IL (1) IL194188A (fr)
MX (1) MX2008012031A (fr)
MY (1) MY146537A (fr)
NO (1) NO20084441L (fr)
NZ (1) NZ571441A (fr)
PL (1) PL2000465T3 (fr)
PT (1) PT2000465E (fr)
RS (1) RS52030B (fr)
SA (1) SA07280131B1 (fr)
SI (1) SI2000465T1 (fr)
TW (1) TWI389894B (fr)
WO (1) WO2007111212A1 (fr)
ZA (1) ZA200805758B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041119A1 (fr) * 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. Dérivés d’hydrazide
CA2647423C (fr) * 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Derive de triazolone
WO2009038157A1 (fr) * 2007-09-21 2009-03-26 Eisai R & D Management Co., Ltd. Dérivé de 2,3-dihydroiminoisoindole
WO2009054791A1 (fr) * 2007-10-26 2009-04-30 Astrazeneca Ab Dérivés de 1,2,4-triazole pyrrolidine fusionnés utilisés en tant que modulateurs de mglur5
EP2212316A4 (fr) * 2007-10-26 2012-06-27 Astrazeneca Ab Dérivés d'amino1,2,4-triazoles en tant que modulateurs du mglur5
TW201206905A (en) * 2010-05-20 2012-02-16 Eisai R & Amp D Man Co Ltd Prodrug of triazolone compound
WO2013134562A1 (fr) * 2012-03-09 2013-09-12 Inception 2, Inc. Composés de triazolone et leurs utilisations
CN102993109A (zh) * 2012-12-03 2013-03-27 浙江工业大学 一种脒化合物的制备方法
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
CN110291383B (zh) * 2017-02-23 2021-12-28 株式会社Ihi Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005000A (en) * 1931-07-18 1935-06-18 L N Miller Engineering Corp Differential motor
EP0019586A1 (fr) 1979-05-11 1980-11-26 Ciba-Geigy Ag Mélanges antithrombotiques
SU1512055A1 (ru) 1987-12-04 1992-07-23 Пермский фармацевтический институт Дигидрохлорид гидразида N-ацетил-N-аллилантраниловой кислоты, про вл ющий антиагрегатную активность по отношению к тромбоцитам плазмы крови
EP1020434A4 (fr) 1997-08-27 2000-11-15 Kissei Pharmaceutical Derives de 3-amidinoaniline, inhibiteurs du facteur x de coagulation sanguine activee, et intermediaires de production de ces derives et de ces inhibiteurs
US6358960B1 (en) 1998-02-17 2002-03-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
DE69920888T2 (de) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
YU41801A (sh) 1998-12-14 2003-12-31 F. Hofman - La Roche Ag. Derivati fenilglicina
WO2000041531A2 (fr) 1999-01-13 2000-07-20 Genentech, Inc. Inhibiteurs de la serine protease
FR2791683A1 (fr) 1999-03-30 2000-10-06 Synthelabo Derives de n-sulfonyl-dipeptides, leur preparation et leur application en therapeutique
FR2793247B1 (fr) 1999-05-04 2001-06-22 Synthelabo Derives de 6-[[(aryl et heteroaryl)oxy]methyl]naphtalene-2- carboximidamide, leur preparation et leur application en therapeutique
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
EP1162194A1 (fr) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Dérivés de (thio)-urée inhibiteurs du facteur VIIa, procédé de leur préparation et leur utilisation
EP1394152A4 (fr) 2001-04-19 2005-02-02 Eisai Co Ltd Derives de 2-iminoimidazole
EP1312602A1 (fr) 2001-11-15 2003-05-21 Eisai Co., Ltd. Dérivés amidino et leur utilisation comme agents anticoagulantes et antithrombotiques
JP4209659B2 (ja) 2001-11-15 2009-01-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 アミジノ誘導体並びにそれを用いた抗血液凝固剤および血栓症治療剤
WO2004032846A2 (fr) * 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Derives de la triazolone et de la triazolethione, inhibiteurs des metalloproteinases de matrices et/ou de l'enzyme de conversion du tnf$g(a)
EP1479679A1 (fr) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Dérivés de triazoles en tant qu'inhibiteurs du facteur Xa
WO2006041119A1 (fr) 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. Dérivés d’hydrazide
DE602005009252D1 (de) 2004-12-08 2008-10-02 Bristol Myers Squibb Co Heterocyclische verbindungen als inhibitoren von faktor viia
CA2647423C (fr) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Derive de triazolone
WO2009038157A1 (fr) 2007-09-21 2009-03-26 Eisai R & D Management Co., Ltd. Dérivé de 2,3-dihydroiminoisoindole

Also Published As

Publication number Publication date
DE602007011231D1 (de) 2011-01-27
BRPI0709101A2 (pt) 2011-06-28
HK1123808A1 (en) 2009-06-26
IL194188A (en) 2013-08-29
US20080015199A1 (en) 2008-01-17
SA07280131B1 (ar) 2010-03-08
US7928228B2 (en) 2011-04-19
MY146537A (en) 2012-08-15
US8163787B2 (en) 2012-04-24
KR20090014341A (ko) 2009-02-10
ATE491694T1 (de) 2011-01-15
ZA200805758B (en) 2009-12-30
ATE557010T1 (de) 2012-05-15
CY1111271T1 (el) 2015-08-05
DK2000465T3 (da) 2011-02-07
EP2000465A4 (fr) 2009-08-26
US7816522B2 (en) 2010-10-19
TWI389894B (zh) 2013-03-21
AU2007230346A1 (en) 2007-10-04
MX2008012031A (es) 2008-10-02
EP2194046B1 (fr) 2012-05-09
PT2000465E (pt) 2011-02-10
CA2647423A1 (fr) 2007-10-04
AU2007230346B2 (en) 2011-12-22
PL2000465T3 (pl) 2011-05-31
CA2647423C (fr) 2015-02-17
EP2194046A1 (fr) 2010-06-09
NO20084441L (no) 2008-12-22
JPWO2007111212A1 (ja) 2009-08-13
NZ571441A (en) 2010-08-27
WO2007111212A1 (fr) 2007-10-04
EP2000465B1 (fr) 2010-12-15
US20110112109A1 (en) 2011-05-12
SI2000465T1 (sl) 2011-04-29
RS52030B (sr) 2012-04-30
TW200745063A (en) 2007-12-16
KR101362024B1 (ko) 2014-02-11
EP2000465A1 (fr) 2008-12-10
JP5016592B2 (ja) 2012-09-05
US20100190783A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
HRP20110054T1 (hr) Derivat triazolona
AU2017258834B2 (en) Multisubstituted aromatic compounds as serine protease inhibitors
JP2021119196A5 (fr)
RU2018141881A (ru) Производные пиразола в качестве ингибиторов калликреина
Kang et al. Hepatic stellate cells: partners in crime for liver metastases?
JP6078639B2 (ja) Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
ES2342783T3 (es) Aril aciltioureas sustituidas y compuestos relacionados, inhibidores de la replicacion viral.
RU2017112739A (ru) Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз
RU2019120990A (ru) Бициклические гетероарильные производные в качестве стимуляторов cftr
JP2014532070A5 (fr)
JP2010515689A5 (fr)
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
RU2017144535A (ru) Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
JP2017535561A5 (fr)
MX2007003321A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
HRP20120969T1 (hr) Spoj azola
RU2014124101A (ru) Использование тиено- и фуро- пиримидинов и пиримидинов в качестве ингибиторов калиевых каналов
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
JP2007519753A5 (fr)
JP2015164972A5 (fr)
US20160280699A1 (en) Substituted phenylalanine derivatives
CA2280727A1 (fr) Aminoacides aromatiques bicycliques
WO2005089731A3 (fr) Utilisation de composes organiques
JP2020526547A5 (fr)
EP1845961B1 (fr) Traitement de troubles thromboemboliques avec du rivaroxaban